Faculty of Medicine, University of Thessaly, BIOPOLIS, Larisa, Greece.
Expert Rev Anti Infect Ther. 2022 Sep;20(9):1163-1169. doi: 10.1080/14787210.2022.2089653. Epub 2022 Jun 19.
Emerging infectious diseases' diagnosis has been a major problem in most hospitals and other senior care facilities, especially for the current Coronavirus Disease 2019 (COVID-19). The various clinical manifestations, and the several radiology and laboratory data combined with the misleading test results for identifying the virus, are responsible for certain misdiagnoses, especially for suspected cases that visit the emergency department and require urgent management and further treatment.
The major challenges for emerging infectious diseases' molecular diagnosis are being described here on a great scale, and, finally, strategies for a precise and on-the-spot molecular diagnosis are thoroughly discussed. Related literature was searched using the PubMed, Science Direct, and EMBASE databases published until May 2022 on the general information for viral infections and relevant false test results.
Emerging diseases' molecular diagnosis via current common diagnostic assays seems to be extremely tricky, and front-line physicians and other senior care facilities should be able to recognize some falsely diagnosed cases or even prevent their existence. Further biotechnologic revolution concerning viral molecular diagnostics will be evident in the near future, thus new methods' limitations should be highlighted to physicians from the very beginning of their performances and wide utilization.
新发传染病的诊断一直是大多数医院和其他高级护理机构的主要问题，特别是当前的 2019 年冠状病毒病（COVID-19）。各种临床表现，以及几种影像学和实验室数据结合病毒的误导性检测结果，导致了某些误诊，特别是对于需要紧急管理和进一步治疗的急诊科疑似病例。
这里大规模描述了新发传染病分子诊断的主要挑战，最后彻底讨论了精确和现场分子诊断的策略。使用 PubMed、Science Direct 和 EMBASE 数据库，检索截至 2022 年 5 月发表的有关病毒感染和相关假检测结果的一般信息的相关文献。
通过当前常见诊断检测方法进行新发疾病的分子诊断似乎非常棘手，一线医生和其他高级护理机构应该能够识别出一些误诊病例，甚至可以防止误诊的发生。在不久的将来，关于病毒分子诊断的生物技术革命将显而易见，因此，从一开始就应该向医生强调新方法的局限性，并广泛利用这些方法。
